Lawrence Klein - Mar 10, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
CBO & COO
Signature
/s/ Michael Esposito, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Mar 10, 2022
Transactions value $
-$192,868
Form type
4
Date filed
3/14/2022, 06:03 PM
Previous filing
Feb 22, 2022
Next filing
Mar 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +4.58K +20.53% 26.9K Mar 10, 2022 Direct F1
transaction CRSP Common Shares Tax liability -$118K -1.88K -7% $62.56 25K Mar 11, 2022 Direct F2
transaction CRSP Common Shares Options Exercise +3K +11.99% 28K Mar 11, 2022 Direct F1
transaction CRSP Common Shares Tax liability -$75.1K -1.23K -4.39% $61.08 26.8K Mar 14, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -4.58K -50.01% 4.58K Mar 10, 2022 Common Shares 4.58K Direct F1, F3
transaction CRSP Restricted Stock Units Options Exercise -3K -25% 9K Mar 11, 2022 Common Shares 3K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.
F4 This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025.